Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

Takamatsu, Kazufumi; Marumo, Satoshi; Fukui, Motonari; Hata, Atsuko

doi:10.1016/j.jmii.2016.11.006

Cited by 8 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Underlining the significant resource consumption in elderly and comorbid patient groups, a retrospective peramivir study between 2012 to 2015 followed elderly inpatients (≥65 years) with influenza and existing comorbidities. Mean length of hospitalization was 14.0 days, with a range from 3‐155 days 52 …”

Section: Resultsmentioning

confidence: 99%

Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta‐analysis

Taniguchi

Ikeda

Hagiwara

et al. 2020

Influenza Resp Viruses

View full text Add to dashboard Cite

Background Elderly populations are particularly vulnerable to influenza and often require extensive clinical support. In Japan, nationwide passive surveillance monitors seasonal influenza but does not capture the full disease burden. We synthesized existing evidence on the epidemiology, vaccine effectiveness (VE), and economic burden of seasonal influenza in the elderly population. Methods PubMed, EMBASE, and ICHUSHI were searched for articles on seasonal influenza in Japan, published between 1997 and 2018, in English or Japanese. Grey literature was also assessed. A random‐effects meta‐analysis characterized VE of influenza vaccines among studies reporting this information. Results Of 1,147 identified articles, 143 met inclusion criteria. Reported incidence rates varied considerably depending on study design, season, study setting and, most importantly, case definition. In nursing homes, the maximum reported attack rate was 55.2% and in the 16 articles reporting mortality rates, case fatality rates varied from 0.009% to 14.3%. Most hospitalizations were in people aged >60; healthcare costs were partially mitigated by vaccine administration. Meta‐analysis estimated overall VE of 19.1% (95% CI: 2.3% ‐ 33.0%) with a high proportion of heterogeneity (I2: 89.1%). There was a trend of lower VE in older people (40.1% [−57.3‐77.2] in the <65 group; 12.9% [−8.0‐29.8] in those 65; P = .21). Conclusions Despite differences between studies that make comparisons challenging, the influenza burden in elderly Japanese is significant. While vaccines are effective, current vaccination programs offer suboptimal protection. Health economic data and cost‐effectiveness analyses were limited and represent areas for policy‐relevant future research.

show abstract

Section: Resultsmentioning

confidence: 99%

Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta‐analysis

Taniguchi

Ikeda

Hagiwara

et al. 2020

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…features have also been conducted, 14,[18][19][20][21][22] peramivir 300 mg single dose or 600 mg repeat dose as an effective antiviral option in patients with chronic respiratory diseases.…”

Section: Discussionmentioning

confidence: 99%

“…Previous head‐to‐head trials of NAIs have focused on the general patient population receiving treatment for acute uncomplicated seasonal influenza 7,8,16,17 . Studies of patients with high‐risk features have also been conducted, 14,18‐22 including with peramivir 300 or 600 mg/d administered for 1‐5 days (mostly 1‐2 days) as needed 14 . This latter trial included patients with diabetes and chronic respiratory diseases and showed a shorter median duration of influenza for patients who received peramivir 600 mg/d compared with 300 mg/d 14 .…”

Section: Discussionmentioning

confidence: 99%

Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study

Kato

Saisho

Tanaka

et al. 2020

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…Current anti-influenza virus drugs include amantadine, rimantadine, oseltamivir, zanamivir and paramivir, which target the life cycle of a virus (2,3). However, worldwide resistance to these drugs due to prolonged usage and the resulting immuno-compromised status already exists (4,5).…”

Section: Introductionmentioning

confidence: 99%

Effect of eleutheroside B1 on non‑coding RNAs and protein profiles of influenza A virus‑infected A549 cells

et al. 2020

View full text Add to dashboard Cite

Influenza viruses often pose a serious threat to animals and human health. In an attempt to explore the potential of herbal medicine as a treatment for influenza virus infection, eleutheroside B1, a coumarin compound extracted from herba sarcandrae, was identified, which exhibited antiviral and anti-inflammatory activities against influenza A virus. In this study, high-throughput RNA sequencing and isobaric tags for relative and absolute quantification (iTRAQ) assays were performed to determine alterations in the non-coding RNA (ncRNA) transcriptome and proteomics. Bioinformatics and target prediction analyses were used to decipher the potential roles of altered ncRNAs in the function of eleutheroside B1. Furthermore, long ncRNA (lncRNA) and mRNA co-expressing networks were constructed to analyze the biological functions by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The analysis of RNA sequencing data revealed that 5 differentially expressed ncRNAs were upregulated and 3 ncRNAs were downregulated in the A549 cells infected with A/PR8/34/H1N1, with or without eleutheroside B1 treatment (PR8+eleu and PR8, respectively). Nuclear paraspeckle assembly transcript 1 (NEAT1) was differentially expressed between the PR8 and A549 cell groups. GO and KEGG pathway analyses indicated that eleutheroside B1 took advantage of the host cell biological processes and molecular function for its antiviral and anti-inflammatory activities, as well as for regulating cytokine-cytokine receptor interaction in the immune system, consistent with previous findings. The results of the iTRAQ assays indicated that L antigen family member 3 (LAGE3) protein, essential for tRNA processing, tRNA metabolic processes and ncRNA processing, was downregulated in the PR8+eleu compared with the PR8 group. In the present study, these comprehensive, large-scale data analysis enhanced the understanding of multiple aspects of the transcriptome and proteomics that are involved in the antiviral and anti-inflammatory activities of eleutheroside B1. These findings demonstrate the potential of eleutheroside B1 for use in the prevention and treatment of influenza A virus-mediated infections.

show abstract

Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

Cited by 8 publications

References 9 publications

Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta‐analysis

Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta‐analysis

Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study

Effect of eleutheroside B1 on non‑coding RNAs and protein profiles of influenza A virus‑infected A549 cells

Contact Info

Product

Resources

About